The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
EYE on CHINA
Verisante Technology, Inc. announces study on nasopharnygeal cancer in China
Verisante Technology, Inc., a leader in cancer detection technology has entered into a collaboration with the BC Cancer Agency and Fujian Normal University in China to develop a new application for the Company’s exclusively licensed platform technology.

Verisante has currently licensed technology from the BC Cancer Agency to develop its Core™ devices, which use an endoscope for the detection of lung, colon, gastro-intestinal and cervical cancers. This new collaboration adds an option to include nasopharyngeal cancer on the list of applications licensed from the BC Cancer Agency to Verisante. The University will be using a nasopharyngeal endoscopic laser Raman system in a study to detect cancerous lesions. Verisante is providing the University with a ClearVu Elite fluorescence endoscopy system. Dr. Haishan Zeng, a distinguished scientist in the Integrative Oncology Department at BC Cancer Agency is leading the development of a nasopharyngeal endoscopic Raman probe. Both the fluorescence imaging system and the Raman spectroscopy probe will be used in the detection and analysis of spectral data collected on patients in China at the Fujian Provincial Tumor Hospital.

“The Verisante Core™ for nasopharyngeal cancer detection has the potential to significantly improve patient outcomes,” said Dr. Zeng, who is also an associate professor of dermatology and skin science at the University of British Columbia in addition to his work at the BC Cancer Agency. “Our collaboration with the Fujian Normal University in China is an important step in testing the technology on real patients in a clinical setting.”

Nasopharyngeal carcinoma is the most common cancer found in the nasopharynx (the upper part of the throat behind the nose). It is fairly rare in North America, but much more common in Southern China and North Africa and was the seventh most fatal cancer in Hong Kong in 2011. The five-year survival rate for people diagnosed with nasopharyngeal cancer is 72 per cent if found early, decreasing to only 38 per cent if found at a later stage.

“We are pleased to continue our partnership with the BC Cancer Agency and to collaborate with a reputed research organization like Fujian Normal University in China,” said Thomas Braun, President and CEO. “While the Company continues to work closely with our exclusive distributors to support sales and marketing efforts of our skin cancer detection device, Aura™, we are also making good progress with Verisante Core™. Adding the nasopharyngeal application and collaboration with China nicely rounds out our continuing portfolio of studies on applications for the Core™, which will be our next product to market. There continues to be high level interest in developing applications for the Core™ in China and throughout the Asian markets.”

Click here for the complete issue.